- Home
- EM vs CHRS Comparison
EM vs CHRS Comparison
Compare EM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EM
- CHRS
- Stock Information
- Founded
- EM 2017
- CHRS 2010
- Country
- EM China
- CHRS United States
- Employees
- EM N/A
- CHRS 235
- Industry
- EM Other Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EM Consumer Discretionary
- CHRS Health Care
- Exchange
- EM Nasdaq
- CHRS Nasdaq
- Market Cap
- EM 297.2M
- CHRS 134.4M
- IPO Year
- EM 2021
- CHRS 2014
- Fundamental
- Price
- EM $1.15
- CHRS $1.21
- Analyst Decision
- EM Strong Buy
- CHRS Strong Buy
- Analyst Count
- EM 1
- CHRS 4
- Target Price
- EM $1.00
- CHRS $5.38
- AVG Volume (30 Days)
- EM 1.9M
- CHRS 2.4M
- Earning Date
- EM 03-27-2025
- CHRS 03-12-2025
- Dividend Yield
- EM 2.29%
- CHRS N/A
- EPS Growth
- EM N/A
- CHRS N/A
- EPS
- EM 0.03
- CHRS N/A
- Revenue
- EM $269,745,696.00
- CHRS $304,340,000.00
- Revenue This Year
- EM N/A
- CHRS $2.47
- Revenue Next Year
- EM $6.16
- CHRS N/A
- P/E Ratio
- EM $35.33
- CHRS N/A
- Revenue Growth
- EM N/A
- CHRS 44.19
- 52 Week Low
- EM $0.46
- CHRS $0.66
- 52 Week High
- EM $1.18
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- EM 81.97
- CHRS 44.03
- Support Level
- EM $1.11
- CHRS $1.03
- Resistance Level
- EM $1.17
- CHRS $1.23
- Average True Range (ATR)
- EM 0.03
- CHRS 0.13
- MACD
- EM -0.00
- CHRS -0.02
- Stochastic Oscillator
- EM 91.89
- CHRS 38.89
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging service through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Through the mini-programs, users rent the power banks to carry with them when use the service and can return the power banks at any of the POIs, enabled by the expansive network and powerful technologies.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.